The rotavirus saga revisited.

Area of Science:

• Pediatric infectious diseases
• Vaccinology
• Public health

Background:

• Rotavirus is a leading cause of severe diarrheal disease in infants globally.
• Concerns regarding intussusception risk with earlier rotavirus vaccines prompted further investigation.
• The US Food and Drug Administration (FDA) approved two new live oral rotavirus vaccines in 2005 and 2008.

Purpose of the Study:

• To evaluate the safety, specifically the risk of intussusception, associated with two new live oral rotavirus vaccines.
• To provide data supporting the widespread use of these rotavirus vaccines in the United States and globally.

Main Methods:

• Large-scale clinical studies involving approximately 70,000 participants each were conducted.
• Intussusception rates were compared between vaccine recipients and placebo recipients.
• Post-marketing surveillance data informed safety assessments.

Main Results:

• Both new rotavirus vaccines demonstrated nearly identical rates of intussusception in both vaccine and placebo groups.
• Extensive use in the United States has yielded positive public health outcomes.
• The vaccines have proven effective in preventing rotavirus gastroenteritis.

Conclusions:

• The two live oral rotavirus vaccines approved in 2005 and 2008 do not pose an increased risk of intussusception.
• These vaccines are safe and effective for preventing rotavirus disease.
• Implementation efforts are ongoing to introduce these vaccines in developing countries where the burden of rotavirus is highest.